SEER Lymphoma Subtype Recode
Understanding of lymphoid neoplasms has evolved over the past 50 years, resulting in numerous classification schemes for these cancers, and particularly for non-Hodgkin lymphomas. In 2007, the International Lymphoma Epidemiology Consortium (InterLymph) Pathology Working Group published a proposed nested classification of lymphoid neoplasms1 based on the World Health Organization classification of lymphoid neoplasms and the International Classification of Diseases-Oncology, Third Edition (ICD-O-3). This classification scheme was designed to facilitate epidemiologic studies of lymphoma subtypes.
The SEER Cancer Statistics Review includes analyses of incidence and survival rates and trends based on the SEER lymphoid malignancy recode variable in Sections 9 and 19 (Hodgkin Lymphoma and Non-Hodgkin Lymphoma, respectively). The SEER lymphoid malignancy recode variable was also added to the SEER databases as a convenience for researchers. The table below contains the variable definitions.
The information provided in this table is also available in an ASCII text file (semicolons are used as the delimiters).
Site Group | Grade | Primary Site | Histology ICD-O-3 | Recode |
---|---|---|---|---|
Lymphoid Neoplasm | ||||
1 Hodgkin Lymphoma | ||||
1(a) Classical Hodgkin lymphoma | ||||
1(a)1 Lymphocyte-rich/mixed cellularity/lymphocyte depleted | ||||
1(a)1.1 Lymphocyte-rich | 0-9 | C000-C809 | 9651 | 01 |
1(a)1.2 Mixed cellularity | 0-9 | C000-C809 | 9652 | 02 |
1(a)1.3 Lymphocyte-depleted | 0-9 | C000-C809 | 9653-9655 | 03 |
1(a)2 Nodular sclerosis | 0-9 | C000-C809 | 9663-9667 | 04 |
1(a)3 Classical Hodgkin lymphoma, NOS | 0-9 | C000-C809 | 9650, 9661-9662 | 05 |
1(b) Nodular lymphocyte predominant Hodgkin lymphoma | 0-9 | C000-C809 | 9659 | 06 |
2 Non-Hodgkin lymphoma | ||||
2(a) Non-Hodgkin lymphoma, B-cell | ||||
2(a)1 Precursor Non-Hodgkin lymphoma, B-cell | 0-9 | C000-C809 | 9728, 9836 | 07 |
6 | C000-C809 | 9727, 9835 | 07 | |
2(a)2 Mature Non-Hodgkin lymphoma, B-cell | ||||
2(a)2.1 Chronic/Small/Prolymphocytic/Mantle B-cell NHL | ||||
2(a)2.1.1 Chronic/Small lymphocytic leuk/lymph | 0-9 | C000-C809 | 9670, 9823 | 08 |
2(a)2.1.2 Prolymphocytic leukemia, B-cell | 0-9 | C000-C809 | 9833 | 09 |
6 | C000-C809 | 9832 | 09 | |
2(a)2.1.3 Mantle-cell lymphoma | 0-9 | C000-C809 | 9673 | 10 |
2(a)2.2 Lymphoplasmacytic lymphoma/Waldenstrom | ||||
2(a)2.2.1 Lymphoplasmacytic lymphoma | 0-9 | C000-C809 | 9671 | 11 |
2(a)2.2.2 Waldenstrom macroglubulinemia | 0-9 | C000-C809 | 9761 | 12 |
2(a)2.3 Diffuse large B-cell lymphoma (DLBCL) | ||||
2(a)2.3.1 DLBCL, NOS | 0-9 | C000-C498, C500-C809 | 9680 | 13 |
6 | C000-C809 | 9684 | 13 | |
2(a)2.3.2 Intravascular large B-cell lymphoma | 0-9 | C499 | 9680 | 14 |
2(a)2.3.3 Primary effusion lymphoma | 0-9 | C000-C809 | 9678 | 15 |
2(a)2.3.4 Mediastinal large B-cell lymphoma | 0-9 | C000-C809 | 9679 | 16 |
2(a)2.4 Burkitt lymphoma/leukemia | 0-9 | C000-C809 | 9687, 9826 | 17 |
2(a)2.5 Marginal-zone lymphoma (MZL) | ||||
2(a)2.5.1 Splenic MZL | 0-9 | C000-C809 | 9689 | 18 |
2(a)2.5.2 Extranodal MZL, MALT type | 0-9 | C000-C769, C780-C809 | 9699 | 19 |
0-9 | C000-C809 | 9760, 9764 | 19 | |
2(a)2.5.3 Nodal MZL | 0-9 | C770-C779 | 9699 | 20 |
2(a)2.6 Follicular lymphoma | 0-9 | C000-C809 | 9690-9691, 9695, 9698 | 21 |
2(a)2.7 Hairy-cell leukemia | 0-9 | C000-C809 | 9940 | 22 |
2(a)2.8 Plasma cell neoplasms | ||||
2(a)2.8.1 Plasmacytoma | 0-9 | C000-C809 | 9731, 9734 | 23 |
2(a)2.8.2 Multiple myeloma/plasma-cell leuk. | 0-9 | C000-C809 | 9732-9733 | 24 |
2(a)2.9 Heavy chain disease | 0-9 | C000-C809 | 9762 | 25 |
2(a)3 Non-Hodgkin lymphoma, B-cell, NOS | 6 | C000-C809 | 9591, 9675 | 26 |
2(b) Non-Hodgkin lymphoma, T-cell | ||||
2(b)1 Precursor Non-Hodgkin lymphoma, T-cell | 0-9 | C000-C809 | 9729, 9837 | 27 |
5, 7, 8 | C000-C809 | 9727, 9835 | 27 | |
2(b)2 Mature Non-Hodgkin lymphoma, T-cell | ||||
2(b)2.1 Mycosis fungoides/Sezary syndrome | ||||
2(b)2.1.1 Mycosis fungoides | 0-9 | C000-C809 | 9700 | 28 |
2(b)2.1.2 Sezary syndrome | 0-9 | C000-C809 | 9701 | 29 |
2(b)2.2 Peripheral T-cell lymphoma | ||||
2(b)2.2.1 Peripheral T-cell lymphoma, NOS | 0-9 | C000-C809 | 9702 | 30 |
5, 7, 8 | C000-C809 | 9675 | 30 | |
2(b)2.2.2 Angioimmunoblastic T-cell lymphoma | 0-9 | C000-C809 | 9705 | 31 |
2(b)2.2.3 Subcutaneous panniculitis-like T-cell lymphoma | 0-9 | C000-C809 | 9708 | 32 |
2(b)2.2.4 Anaplastic large cell lymphoma, T- or Null-cell | 0-9 | C000-C809 | 9714 | 33 |
2(b)2.2.5 Hepatosplenic T-cell lymphoma | 0-9 | C000-C809 | 9716 | 34 |
2(b)2.2.6 Enteropathy-type T-cell lymphoma | 0-9 | C000-C809 | 9717 | 35 |
2(b)2.2.7 Cutaneous T-cell lymphoma, NOS | 0-9 | C000-C809 | 9709 | 36 |
2(b)2.2.8 Primary cutaneous anaplastic large cell lymphoma | 0-9 | C000-C809 | 9718 | 37 |
2(b)2.3 Adult T-cell leukemia/lymphoma | 0-9 | C000-C809 | 9827 | 38 |
2(b)2.4 NK/T-cell lymph., nasal-type/aggressive NK leuk. | 0-9 | C000-C809 | 9719, 9948 | 39 |
2(b)2.5 T-cell large granular lymphocytic leukemia | 0-9 | C000-C809 | 9831 | 40 |
2(b)2.6 Prolymphocytic leukemia, T-cell | 0-9 | C000-C809 | 9834 | 41 |
5, 7, 8 | C000-C809 | 9832 | 41 | |
2(b)3 Non-Hodgkin lymphoma, NOS, T-cell | 5, 7, 8 | C000-C809 | 9591, 9684 | 42 |
2(c) Non-Hodgkin lymphoma, unknown lineage | ||||
2(c)1 Precursor lymphoblastic leuk/lymph, unknown lineage | 1-4, 9 | C000-C809 | 9727, 9835 | 43 |
2(c)2 Prolymphocytic leukemia, unknown lineage | 1-4, 9 | C000-C809 | 9832 | 44 |
2(c)3 Non-Hodgkin lymphoma, NOS, unknown lineage | 1-4, 9 | C000-C809 | 9591, 9675, 9684 | 45 |
3 Composite Hodgkin lymphoma and NHL | 0-9 | C000-C809 | 9596 | 46 |
4 Lymphoid neoplasm, NOS | 0-9 | C000-C809 | 9590, 9594, 9820, 9970 | 47 |
Unclassified | 99 |
1 Adapted from Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695-708.